Details for Patent: 11,026,931

Which drugs does patent 11,026,931 protect, and when does it expire?

Patent 11,026,931 protects INGREZZA and INGREZZA SPRINKLE and is included in two NDAs.

This patent has eighteen patent family members in sixteen countries.

Summary for Patent: 11,026,931

Scope and claims summary:

Title:	Methods for the administration of certain VMAT2 inhibitors
Abstract:	Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.
Inventor(s):	Liang; Grace S. (San Diego, CA), O'Brien; Christopher F. (Vashon, WA), Thai-Cuarto; Dao Tuyet (San Diego, CA)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	16/983,334
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 11,026,931

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017	AB	RX	Yes	No						TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021	AB	RX	Yes	No						TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-002	Oct 4, 2017	AB	RX	Yes	Yes						TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA SPRINKLE	valbenazine tosylate	CAPSULE;ORAL	218390-001	Apr 30, 2024		RX	Yes	No						TREATMENT OF TARDIVE DYSKINESIA

International Family Members for US Patent 11,026,931

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019322863
Brazil	112021000019
Canada	3104693
China	112867491